Memórias do Instituto Oswaldo Cruz
Fundação Oswaldo Cruz, Fiocruz
Vol. 96, No. 3, 2001, pp. 343-348
Bioline Code: oc01050
Full paper language: English
Document type: Research Article
Document available free of charge
Memórias do Instituto Oswaldo Cruz, Vol. 96, No. 3, 2001, pp. 343-348
© Copyright 2001 Fundacao Oswaldo Cruz Fiocruz
Effect of Interferon-a on Experimental Septal Fibrosis of the Liver - Study with a New Model|
Marcia Maria de Souza; Raymundo Paraná; Christian Trepo; Aryon A Barbosa Jr; Irismar Oliveira & Zilton A Andrade
Interferon-a is used in antiviral therapy in humans, mainly for viral hepatitis B and C. An anti-fibrotic effect of interferon has been postulated even in the absence of anti-viral response, which suggests that interferon directly inhibits fibrogenesis. Rats infected with the helminth Capillaria hepatica regularly develop diffuse septal fibrosis of the liver, which terminates in cirrhosis 40 days after inoculation.
The aim of this study was to test the anti-fibrotic effect of interferon in this experimental model. Evaluation of fibrosis was made by three separate methods: semi-quantitative histology, computerized morphometry and hydroxyproline measurements. Treatment with interferon-a proved to inhibit the development of fibrosis in this model, especially when doses of 500,000 and 800,000 IU were used for 60 days. Besides confirming the anti-fibrotic potential of interferon-a on a non-viral new experimental model of hepatic fibrosis, a clear-cut dose-dependent effect was observed.
interferon-a, hepatic fibrosis, Capillaria hepatica
Alternative site location: http://memorias.ioc.fiocruz.br